capecitabine has been researched along with epirubicin in 177 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 46 (25.99) | 29.6817 |
| 2010's | 116 (65.54) | 24.3611 |
| 2020's | 15 (8.47) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Angiolini, C; Baldini, A; Bergaglio, M; Canavese, G; Del Mastro, L; Garrone, O; Lambiase, A; Merlano, M; Rosso, R; Tolino, G; Venturini, M | 1 |
| Blackie, R; Evans, TR; Fullarton, GM; McDonald, AC; McInnes, A; Morrison, R; Paul, J; Pentheroudakis, G; Raby, N; Soukop, M | 1 |
| Budman, DR | 1 |
| André, T; Artru, P; Louvet, C | 1 |
| Aapro, M; O'Shaughnessy, J; Twelves, C | 1 |
| Bighin, C; Colozza, MA; Contu, A; Del Mastro, L; Durando, A; Garrone, O; Genta, F; Lambiase, A; Stevani, I; Venturini, M | 1 |
| Atalay, G; Biganzoli, L; Bonnefoi, H; Cufer, T; Mauriac, L; Piccart, M; Schaefer, P | 1 |
| Hozumi, Y; Ito, Y; Iwata, H; Kobayashi, T; Morita, S; Ohno, S; Sakamoto, J; Toi, M | 1 |
| Palmieri, FM; Perez, EA; Tack, DK | 1 |
| Becerra, CR | 1 |
| Bartsch, R; Gnant, MF; Hussian, D; Jakesz, R; Locker, GJ; Pluschnig, U; Sevelda, U; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Cunningham, D; Harper-Wynne, C; Hickish, T; Hill, M; Iveson, T; Nicolson, M; Norman, AR; Oates, J; Rao, S; Sumpter, K; Tebbutt, N; Ward, C | 1 |
| Crivellari, D; Goldhirsch, A; Graffeo, R; Hess, D; Lombardi, D; Longhi, S; Munzone, E; Nolè, F; Pagani, O; Ruggeri, M; Sessa, C; Thürlimann, B | 1 |
| Bang, SM; Cho, EK; Im, SA; Lee, JH; Lee, SN; Lee, WK; Park, DK; Park, SH; Park, YH; Shin, DB | 1 |
| Bang, SM; Cho, EK; Lee, JH; Lee, JN; Park, SH; Park, YH; Shin, DB | 1 |
| Hamada, K; Kubota, K; Mori, S; Nakagawa, A; Suzuki, N; Tagaya, N | 1 |
| Boot, H; Corporaal, S; Legdeur, MC; Russel, MG; Smit, WM; van der Palen, J | 1 |
| Carrato Mena, A; Gallego Plazas, J; Maciá Escalante, S; Martínez Banaclocha, N; Rodríguez Lescure, A | 1 |
| Berton-Rigaud, D; Bourbouloux, E; Bouriel, C; Bridji, B; Campion, L; Campone, M; Chatal, JF; Clouet, M; Delecroix, V; Devillers, A; Doutriaux, I; Ferrer, L; Garin, E; Kerbrat, P; Resche, I; Ricaud, M; Rouquette, S; Rousseau, C; Sagan, C | 1 |
| Ahlgren, J; Bergh, J; Bergström, D; Blomqvist, C; Lidbrink, E; Lindh, B; Malmberg, L; Nordgren, H; Ohd, JF; Villman, K | 1 |
| Dupont, J; Jensen, BV; Jensen, HA; Pfeiffer, P | 1 |
| Filip, DJ; Grossniklaus, HE; Lee, WB; Sy, HM | 1 |
| Cantore, M; Del Freo, A; Fiorentini, G; Mambrini, A; Orlandi, M; Pacetti, P; Torri, T | 1 |
| Chow, LW; Loo, WT; Sasano, H | 1 |
| Ajani, JA; Cen, P | 1 |
| Coxon, F; Cunningham, D; Daniel, F; Iveson, T; Middleton, G; Nicolson, M; Norman, AR; Oates, J; Rao, S; Starling, N | 2 |
| Hozumi, Y; Ito, Y; Iwata, H; Kobayashi, T; Morita, S; Ohno, S; Saji, S; Sakamoto, J; Toi, M | 1 |
| Borghesi, S; Hawkins, MA; Tait, D | 1 |
| Hino, N; Ikushima, Y; Miyake, H; Ogasawara, T; Ohura, R; Sohnaka, Y; Tsuyuguchi, M; Wada, D; Yamamoto, Y; Yamasaki, S | 1 |
| Becerra, CR; Frenkel, EP; Tavana, D; Tran, HT; Verma, UN; Williams, NS | 1 |
| Eggemann, H; Elling, D; Harbeck, N; Janni, W; Kaufmann, M; Kiechle, M; Kümmel, S; Loibl, S; Nekljudova, V; Sommer, H; von Minckwitz, G | 1 |
| Gennatas, K; Gennatas, S; Michalaki, V | 1 |
| Jensen, BY; Jensen, HA; Larsen, O; Pfeiffer, P; Schønnemann, KR; Yilmaz, M | 1 |
| Baselga, J; Benson, M; Cunningham, D; Hill, A; Kurek, R; Lüpfert, C; Oates, J; Rao, S; Starling, N; Wotherspoon, A | 1 |
| Kolluri, RB; Raouf, S; Tipples, K | 1 |
| Arcidiacono, PG; Balzano, G; Cereda, S; Di Carlo, V; Mazza, E; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E; Zerbi, A | 1 |
| Lau, SC; Shibata, SI | 1 |
| Allum, W; Ashley, S; Benson, M; Brown, G; Chau, I; Cunningham, D; Oates, J; Okines, A; Riddell, A; Starling, N; Stavridi, F; Thomas, J; Thompson, J; Wotherspoon, A | 1 |
| Cantore, M; Del Freo, A; Mambrini, A; Orlandi, M; Pacetti, P; Pezzuolo, D; Seta, RD; Tartarini, R; Torri, T | 1 |
| Cantore, M; Danesi, R; Del Freo, A; Del Tacca, M; Giovannetti, E; Mambrini, A; Nannizzi, S; Orlandi, M; Pacetti, P; Tartarini, R | 1 |
| Berry, H; Dodwell, DJ; Gillibrand, A; Kumar, S; Perren, TJ; Velikova, G; Waters, SH | 1 |
| Ashley, S; Chau, I; Cunningham, D | 1 |
| Aramendía, JM; Arbea, L; Aristu, J; De la Cruz, S; Espinós, J; Fernández-Hidalgo, O; Martínez-Monge, R; Moreno, M; Nieto, Y; Pina, L; Regueira, FM; Santisteban, M; Sola, J; Zornoza, G | 1 |
| Fareed, KR; Ilyas, M; Kaye, PV; Lobo, DN; Madhusudan, S; Parsons, SL; Soomro, IN | 1 |
| Hayashida, T; Ikeda, T; Jinno, H; Kitagawa, Y; Mukai, M; Sakata, M; Takahashi, M | 1 |
| Beal, K; Damast, S; Elkin, E; Fornier, MN; Ho, AY; Ishill, N; McCormick, B; Montgomery, L | 1 |
| Ahlgren, J; Asola, R; Auvinen, P; Bono, P; Helle, L; Hemminki, A; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Lahtela, SL; Lehtiö, K; Leinonen, M; Lindman, H; Nilsson, G; Nuortio, L; Nyandoto, P; Paija, O; Pajunen, M; Poikonen, P; Tanner, M; Villman, K | 1 |
| Ardavanis, A; Christophyllakis, C; Georgoulias, V; Kakolyris, S; Kentepozidis, N; Kouroussis, C; Malamos, N; Mavroudis, D; Papakotoulas, P; Polyzos, A; Syrigos, K; Ziras, N | 1 |
| Kang, WK; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Yun, J | 1 |
| Ashley, S; Cunningham, D; Okines, AF | 1 |
| Bauerfeind, I; Blohmer, JU; Dan Costa, S; du Bois, A; Eidtmann, H; Fasching, PA; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Kaufmann, M; Kühn, T; Loibl, S; Mehta, K; Rezai, M; Tesch, H; Thomssen, C; Untch, M; von Minckwitz, G | 2 |
| Eidtmann, H; Fehm, T; Hilfrich, J; Holms, F; Huober, J; Komor, M; Loibl, S; Müller, V; Pantel, K; Rau, T; Riethdorf, S; Roller, M; Schrader, I; Tesch, H; Untch, M; von Minckwitz, G; Zhang, L | 1 |
| Feng, M; Qiu, F; Xiang, XJ; Xiong, JP; Yu, F; Zhan, ZY; Zhang, L | 1 |
| Archer, C; Beadman, C; Cunningham, D; Gilligan, D; Kurek, R; Oates, J; Rao, S; Ruhstaller, T; Starling, N; Sumpter, K; Valladares-Ayerbes, M; Wilke, H | 1 |
| Ashley, SE; Chau, I; Chua, YJ; Cunningham, D; Oates, J; Okines, AF; Saffery, C; Turner, A; Webb, J | 1 |
| Brandberg, Y; Einbeigi, Z; Hatschek, T; Johansson, H; Svensson, H | 2 |
| Isufi, I; Kaley, K; Saif, MW; Syrigos, K | 1 |
| Borowicz, H; Glados, M; Heilmann, V; Hinke, A; Jackisch, C; Lehnert, A; Möbus, V; Müller, V; Schmidt, M; Thomssen, C | 1 |
| de Jongh, FE; Eskens, FA; Konings, IR; Sleijfer, S; van der Gaast, A; van der Wijk, LJ | 1 |
| Hu, W; Li, L; Sheng, Y; Shi, J; Su, D; Wang, CK | 1 |
| Gossage, JA; Hale, PC; Mamidanna, R; Manifold, DK; Newman, G; Pantling, AZ; Robinson, A | 1 |
| Botti, G; D'Aiuto, G; De Maio, E; de Matteis, A; Di Bonito, M; Di Maio, M; Di Rella, F; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rinaldo, M; Rossi, E; Thomas, R | 1 |
| Boc, M; Hlebanja, Z; Ocvirk, J; Reberšek, M; Skof, E | 1 |
| Bassi, C; Cantore, M; Fiorentini, G; Mambrini, A; Orlandi, M; Torri, T | 1 |
| Cunningham, D; Hawkes, EA; Okines, AF; Plummer, C | 1 |
| Danso-Appiah, A; Eastwood, A; Norman, G; Palmer, S; Rice, S; Spackman, E; Stirk, L; Suh, D | 1 |
| Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E | 1 |
| Clemens, MR; Darb-Esfahani, S; Denkert, C; Diebold, K; Dietrich, K; Eidtmann, H; Hanusch, C; Henschen, S; Hoffmann, G; Holms, F; Huober, J; Just, M; Loibl, S; Schrader, I; Solbach, C; Tesch, H; Tiemann, K; Untch, M; von Minckwitz, G | 1 |
| Abel, U; Debus, J; Haag, GM; Haberkorn, U; Jäger, D; Lordick, F; Lorenzen, S; Münter, MW; Stange, A; von Gall, C; Weichert, W; Weitz, J | 1 |
| Agostini, C; Bachelot, T; Bajard, A; Boisseau, M; Coeffic, D; Dramais, D; Ferri-Dessens, RM; Guastalla, JP; Kaphan, R; Oprea, C; Perol, D; Provencal, J; Ray-Coquard, I | 1 |
| Brodowicz, T; Csörgo, E; Kahán, Z; Kaizer, L; Lázár, G; Nikolényi, A; Ormándi, K; Sükösd, F; Thurzó, L; Uhercsák, G; Vörös, A | 1 |
| Boot, H; Cats, A; Dikken, JL; Jansen, EP; Lind, PA; Maurits Swellengrebel, HA; Putter, H; van de Velde, CJ; van Grieken, NC; van Sandick, JW; Verheij, M | 1 |
| Lolkema, MP; van der Horst, S; van der Sluis, PC; van Hillegersberg, R; Verhage, RJ | 1 |
| Ashley, S; Chau, I; Cunningham, D; Gujral, DM; Hawkins, MA; Leonulli, BG; Tait, D | 1 |
| Aström, G; Bergh, J; Brandberg, Y; Carlsson, L; Carstensen, J; Einbeigi, Z; Fernö, M; Hatschek, T; Hellström, M; Lidbrink, E; Linderholm, B; Lindh, B; Loman, N; Malmberg, M; Rotstein, S; Söderberg, M; Sundquist, M; Svensson, H; Walz, TM | 1 |
| Ahlgren, J; Asola, R; Auvinen, P; Bono, P; Helle, L; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Leinonen, M; Lindman, H; Nilsson, G; Nyandoto, P; Paija, O; Pajunen, M; Poikonen, P; Tanner, M; Villman, K | 1 |
| Helin, H; Karhumäki, L; Kauppi, JT; Kemppainen, J; Oksala, N; Räsänen, JV; Salo, JA; Sihvo, EI | 1 |
| Booser, DJ; Brewster, AM; Broglio, K; Buzdar, AU; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Hunt, KK; Ibrahim, NK; Kelly, CM; Thomas, ES; Valero, V; Walters, RS | 1 |
| Bains, S; Madhavarao, B; Mutyala, V; Patil, C | 1 |
| Bouchardy, C; Dehler, S; Ess, S; Frick, H; Joerger, M; Konzelmann, I; Savidan, A; Thürlimann, B | 1 |
| Arasaradnam, RP; Borman, RA; Goodyear, SJ; James, S; Jarvie, EM; Nwokolo, CU; Sanger, GJ; Snead, D; Sung, EZ | 1 |
| Aparicio, J; Dueñas, R; Falcó, E; Gómez-Martin, C; Irigoyen, A; Lacasta, A; Llorente, B; López, RL; Muñoz, ML; Pérez, B; Reboredo, M; Regueiro, P; Safont, MJ; Sánchez, A; Sanchez-Viñes, E; Serrano, R | 1 |
| Allum, WH; Blazeby, JM; Coxon, F; Cunningham, D; Evans, L; Falk, S; Ford, D; Griffin, M; Hall, M; Iveson, TJ; Langley, RE; Middleton, GW; Okines, AF; Petty, RD; Plummer, C; Seymour, M; Slater, S; Smith, D; Stenning, SP; Stevenson, L; Thompson, LC; Waters, J | 1 |
| Hayashida, T; Hirose, S; Ikeda, T; Jinno, H; Kitagawa, Y; Matsuda, S; Takahashi, M | 1 |
| Aström, G; Blomqvist, L; Carlsson, L; Einbeigi, Z; Fujii, H; Glimelius, B; Hatschek, T; Jacobsson, H; Linderholm, B; Lindh, B; Loman, N; Malmberg, M; Rotstein, S; Söderberg, M; Sundqvist, M; Suzuki, C; Walz, TM | 1 |
| Cai, G; Li, G; Ma, X; Zhang, Z; Zhu, J | 1 |
| Asari, R; Ba-Ssalamah, A; Birner, P; Datler, P; Hejna, M; Pluschnig, U; Preusser, M; Schoppmann, SF; Schwameis, K; Zacherl, J | 1 |
| Behera, J; Chatterjee, S; Gajalakshmi, P; Madhuwanti, S; Muthumani, K; Pradeep, T; Priya, MK; Saran, U | 1 |
| Barbachano, Y; Chau, I; Coxon, F; Crosby, T; Cunningham, D; Falk, S; Ferry, D; Frances, A; Gonzalez, D; Iveson, T; Mansoor, W; Middleton, G; Okines, AF; Okines, C; Peckitt, C; Saffery, C; Slater, S; Smith, D; Waddell, T; Wadsley, J; Waters, J; Wotherspoon, A | 1 |
| Bowrey, DJ; Cunnell, M; Khanna, A; Madhusudan, S; Parsons, SL; Reece-Smith, AM; Thomas, A | 1 |
| Beckmann, M; Du Bois, A; Eidtmann, H; Heilmann, V; Hubalek, M; Huober, J; Jackisch, C; Loibl, S; Lück, HJ; Richter, B; Schrader, I; Schuster, T; Stähler, A; Stickeler, E; Thomssen, C; Untch, M; von Minckwitz, G; Wollschläger, K | 1 |
| Asari, R; Ba-Ssalamah, A; Birner, P; Hejna, M; Ilhan-Mutlu, A; Pluschnig, U; Preusser, M; Püspök, A; Schoppmann, SF; Schwameis, K; Zacherl, J | 1 |
| Ahlgren, J; Auvinen, P; Bono, P; Helle, L; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Leinonen, M; Lindman, H; Nilsson, G; Nyandoto, P; Saarni, O; Tanner, M; Villman, K | 1 |
| Barinoff, J; Bauerfeind, I; Belau, A; Clemens, M; Conrad, B; Diel, IJ; Elling, D; Forstbauer, H; Harbeck, N; Huober, J; Jackisch, C; Kreienberg, R; Loibl, S; Lück, HJ; Möbus, V; Müller, V; Nekljudova, V; Noeding, S; Schmidt, M; Schneeweiss, A; Thomssen, C; Untch, M; von Minckwitz, G | 1 |
| Fang, P; Ji, TF; Liu, H; Shi, WW; Yang, B; Yang, JL; Zhu, YY | 1 |
| Aogi, K; Bando, H; Chow, LW; Fakhrejahani, E; Hisamatsu, K; Ito, Y; Iwata, H; Kamigaki, S; Kashiwaba, M; Kuroi, K; Masuda, N; Morimoto, T; Nakamura, S; Nakayama, T; Ohno, S; Sasano, H; Sato, N; Takahashi, F; Toi, M; Ueno, T; Yamamoto, Y; Yamashita, H; Yoshida, N | 1 |
| Bailey, IS; Byrne, JP; Curtis, NJ; Kelly, JJ; Noble, F; Underwood, TJ | 1 |
| Bauerfeind, I; Blohmer, JU; Costa, SD; Denkert, C; Eidtmann, H; Fasching, PA; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Kümmel, S; Loibl, S; Mehta, K; Paepke, S; Rezai, M; Schneeweiss, A; Tesch, H; Untch, M; von Minckwitz, G | 1 |
| Agterof, M; Borel-Rinkes, I; Lolkema, MP; Overkleeft, E; Reerink, O; Schipper, M; Siersema, P; Ubink, I; van der Sluis, P; van Hillegersberg, R; Vleggaar, F; Voest, E; Wijrdeman, H | 1 |
| Bartsch, R; Dubsky, P; Fesl, C; Fitzal, F; Gampenrieder, SP; Gnant, M; Greil, R; Hartmann, BL; Hubalek, M; Jakesz, R; Lang, A; Melbinger, E; Mlineritsch, B; Muss, C; Petzer, AL; Ressler, S; Rudas, M; Singer, CF; Steger, GG; Stoeger, H; Zielinski, CC | 1 |
| Arango, B; Escobar, M; Hosein, PJ; Kittaneh, M; Kyriakopoulos, C; Loaiza-Bonilla, A; Merchan, JR; Ochoa, RE; Palacio, S; Restrepo, MH; Rocha Lima, CM | 1 |
| Rau, B | 1 |
| Cserni, G; Csörgő, E; Kelemen, G; Kővári, B; Lázár, P; Nyári, T; Rusz, O; Vörös, A | 1 |
| Higaki, K; Kuroi, K; Masuda, N; Matsunami, N; Miyamoto, T; Mizutani, M; Morimoto, T; Morita, S; Ohno, S; Ohtani, S; Takano, T; Toi, M | 1 |
| Kalachand, R; King, S; Mongan, AM; Muldoon, C; O'Byrne, K; O'Farrell, NJ; Power, D; Ravi, N; Reynolds, JV | 1 |
| Anderson, A; Davidenko, I; Deptala, A; Donehower, RC; Dubey, S; Harrison, M; Iveson, T; Jiang, Y; Lakshmaiah, K; Loh, E; Nirni, S; Oliner, KS; Tang, R; Thomas, A; Tjulandin, S; Zhu, M | 1 |
| Guo, X; Jiao, S; Jing, F; Li, J; Linghu, R; Liu, M; Yang, J; Zhu, Y | 1 |
| André, T; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Boucher, E; Etienne, PL; Gornet, JM; Guimbaud, R; Hammel, P; Louvet, C; Maillard, E; Nguyen, S; Rebischung, C; Ries, P; Rougier, P; Ychou, M | 1 |
| Brammer, K; Catton, JA; James, EJ; Parsons, SL; Randhawa, N; Tan, BH; Welch, NT | 1 |
| Boonstra, JJ; Borel Rinkes, IH; Lolkema, MP; Los, M; Ruurda, JP; Schipper, ME; Siersema, PD; Ubink, I; van der Horst, S; van der Sluis, PC; van Hillegersberg, R; Voest, EE; Wiezer, MJ | 1 |
| Doshi, S; Gisleskog, PO; Loh, E; Oliner, KS; Perez Ruixo, JJ; Zhang, Y; Zhu, M | 1 |
| Fisker, RV; Frøkjær, JB; Iyer, V; Kristensen, SR; Larsen, AC; Mortensen, PB; Møller, B; Thorlacius-Ussing, O; Yilmaz, MK | 1 |
| Bichev, D; Breithaupt, K; Daum, S; Dogan, Y; Schmidt, SC; Thuss-Patience, PC; Treese, C; von Winterfeld, M | 1 |
| Berdel, WE; Brehler, AC; Hartmann, W; Kerkhoff, A; Kessler, T; Lenze, F; Palmes, D; Schliemann, C; Senninger, N; Ullerich, H; Wiebe, S | 1 |
| Abraham, J; Basu, B; Brenton, J; Earl, H; Freeman, S; Gounaris, I; Hatcher, H; Hosking, K; Iddawela, M; Jimenez-Linan, M; Moyle, P; Parkinson, C; Sayal, K | 1 |
| Calpena, R; Gallego, J; Lacueva, FJ; Martinez-Blasco, A; Mingol, F; Morcillo, MA; Moya, P; Orduña, A; Ruiz, JA; Sola-Vera, J | 1 |
| Alfer, J; Burchardi, N; Conrad, B; Decker, T; Denkert, C; Eidtmann, H; Eiermann, W; Hackmann, J; Huober, J; Jackisch, C; Loibl, S; Marmé, F; Möbus, V; Nekljudova, V; Potenberg, J; Reimer, T; Simon, E; Stickeler, E; Thomssen, C; von Minckwitz, G | 1 |
| Brunetti, O; Caldarola, L; Dell'Endice, S; Mangia, A; Monti, M; Santini, D; Saragoni, L; Scarpi, E; Silvestris, N; Simone, G | 1 |
| Allum, WH; Chaudry, MA; Messager, M; Neofytou, K | 1 |
| Bronsert, P; Glatz, T; Hoeppner, J; Hopt, UT; Kulemann, B; Makowiec, F; Marjanovic, G; Schäfer, M; Sick, O; Zirlik, K | 1 |
| Budzynski, A; Fijorek, K; Konopka, K; Krzemieniecki, K; Lazar, A; Matlok, M; Ochenduszko, S; Pedziwiatr, M; Puskulluoglu, M; Sinczak-Kuta, A; Urbanczyk, K | 1 |
| Adrover, E; Andrés, R; Baena-Cañada, JM; Ballesteros, AI; Barnadas, A; Calvo, L; Carrasco, EM; Casas, M; de la Haba-Rodríguez, J; Del Barco Berron, S; del Carmen Cámara, M; González, S; Jara, C; Lluch, A; López-Vega, JM; Margelí Vila, M; Martín, M; Martínez de Dueñas, E; Martínez-Jáñez, N; Mendiola Fernández, C; Muñoz-Mateu, M; Plazaola, A; Ramos, M; Ribelles, N; Rodríguez, CA; Rodríguez-Lescure, Á; Ruiz Borrego, M; Ruiz Simón, A; Sánchez-Rovira, P; Santaballa, A | 1 |
| Azmi, S; Fadavi, H; Ferdousi, M; Malik, I; Malik, RA; Mansoor, W; Marshall, A; Petropoulos, IN; Ponirakis, G; Tavakoli, M | 1 |
| Balzano, G; Belli, C; Ceraulo, D; Cereda, S; Di Terlizzi, G; Doglioni, C; Dugnani, E; Falconi, M; Lampasona, V; Liberati, D; Maggiora, P; Nicoletti, R; Pasquale, V; Piemonti, L; Reni, M; Scavini, M; Sordi, V | 1 |
| Darb-Esfahani, S; Denkert, C; Eidtmann, H; Fasching, PA; Furlanetto, J; Hartmann, A; Huober, J; Jackisch, C; Klimowicz, A; Lederer, B; Loibl, S; Mehta, K; Pfitzner, B; Tiemann, K; Untch, M; von Minckwitz, G | 1 |
| Caruso, R; D'Andrea, V; Diaz, E; Duran, H; Fabra, I; Ferri, V; Ferronetti, A; Ielpo, B; Malave, L; Plaza, C; Quijano, Y; Vicente, E | 1 |
| Arshad, A; Bowrey, DJ; Calder, PC; Dennison, AR; Eltweri, AM; Fisk, HL; Thomas, AL | 1 |
| Denkert, C; Eiermann, W; Furlanetto, J; Lederer, B; Loibl, S; Marmé, F; Möbus, V; Nekljudova, V; Reimer, T; Reinisch, M; Schmatloch, S; Stickeler, E; Thomssen, C; Untch, M; von Minckwitz, G; Weber, K | 1 |
| Hou, J; Ji, Y; Liu, FL; Liu, TS; Shen, KT; Shen, ZB; Sun, YH; Wang, Y; Yu, S; Yu, YY; Zhao, NQ; Zhuang, RY | 1 |
| Doshi, S; Hoang, T; Kasichayanula, S; Kuchimanchi, M; Zhang, Y; Zhu, M | 1 |
| Anthoney, A; Cheeseman, S; Collinson, M; Dent, J; Hall, PS; Howard, H; Jones, M; Last, K; Lord, SR; Lowe, C; Marshall, H; Roy, R; Seymour, MT; Swinson, D; Velikova, G | 1 |
| Ahlgren, J; Auvinen, P; Bono, P; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Junnila, J; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Kosonen, S; Lahdenperä, O; Lindman, H; Nilsson, G; Nyandoto, P; Poikonen-Saksela, P; Tanner, M; Villman, K | 1 |
| Bowman, CR; Dorrington, MS; Kaye, P; Madhusudan, S; Mumtaz, E; Pang, V; Parsons, SL; Reece-Smith, AM; Saunders, JH; Soomro, I | 1 |
| Goense, L; Haj Mohammad, N; Meijer, GJ; Mook, S; Ruurda, JP; van der Horst, S; van der Sluis, PC; van Hillegersberg, R; van Rossum, PSN; van Vulpen, M | 1 |
| Anderegg, MCJ; Gisbertz, SS; Hulshof, MCCM; Los, M; Mohammed, NH; Ruurda, JP; van Berge Henegouwen, MI; van der Sluis, PC; van Hillegersberg, R; van Laarhoven, HWM; van Vulpen, M; Wiezer, MJ | 1 |
| Bauerfeind, I; Conrad, B; du Bois, A; Elling, D; Fehm, T; Harbeck, N; Huober, J; Jackisch, C; Loibl, S; Lück, HJ; Möbus, V; Müller, V; Nekljudova, V; Schneeweiss, A; Tesch, H; Thomssen, C; Untch, M; von Minckwitz, G | 1 |
| Bruns, CJ; Schröder, W | 1 |
| Denkert, C; Forstbauer, H; Hoffmann, G; Karn, T; Kohls, A; Köhne, CH; Linn, SC; Loibl, S; Marmé, F; Möbus, VJ; Nekljudova, V; Schem, C; Schmatloch, S; Schouten, PC; Solbach, C; Thomssen, C; van Rossum, AGJ; von Minckwitz, G; Weber, KE | 1 |
| Ahmed, M; Amir, M; Hassan, S; Khan, K; Khokhar, N; Nasir, H | 1 |
| Joensuu, H; Lindman, H | 1 |
| Altundag, K | 1 |
| Bergh, J; Brage, SE; Carlsson, L; Einbeigi, Z; Fernö, M; Foukakis, T; Hatschek, T; Linderholm, B; Loman, N; Lorent, J; Lövrot, J; Malmberg, M; Matikas, A; Skoog, L; Suzuki, C; Tobin, N; Zerdes, I | 1 |
| Hoehler, T; Kanzler, S; Kunzmann, V; Lordick, F; Maderer, A; Meyer, HJ; Mihaljevic, AL; Moehler, M; Mönig, S; Sandermann, A; Schroll, S; Schuhmacher, C; Stahl, M; Tannapfel, A; Thuss-Patience, P; Wilke, H | 1 |
| Braak, JPBM; Cats, A; Claassen, YHM; de Steur, WO; Dikken, JL; Hartgrink, HH; Jansen, EPM; Meershoek-Klein Kranenbarg, WM; Putter, H; Trip, AK; van Berge Henegouwen, MI; van de Velde, CJH; van Grieken, NCT; van Sandick, JW; Verheij, M | 1 |
| Hepworth, R; Smith, E; Tin, AW; Wadd, N; Walker, J; Wilson, D | 1 |
| Huang, Q; Jiang, Y; Li, Q; Li, S; Liu, J; Wei, W; Yang, H | 1 |
| Aparicio, T; Azzedine, A; Barbier, E; Bouche, O; Chapelle, N; Cohen, R; Dahan, L; Etienne, PL; Gornet, JM; Guimbaud, R; Hammel, P; Le Malicot, K; Lepage, C; Louvet, C; Mineur, L; Nguyen, S; Phelip, JM; Samalin, E; Sefrioui, D; Touchefeu, Y | 1 |
| Anthoney, A; Germetaki, T; Kamposioras, K; Kordatou, Z; Mansoor, W; Nasralla, M; Owen-Holt, V; Papaxoinis, G; Stamatopoulou, S; Weaver, JMJ | 1 |
| Bowrey, DJ; Chung, WY; Dennison, AR; Eltweri, AM; Morgan, B; Thomas, AL; Thompson, J | 1 |
| Ålgars, A; Kemppainen, J; Ristamäki, R; Salminen, P; Sundström, J; Vihervaara, H | 1 |
| Cho, H; Kang, YK | 1 |
| Bradley, CA | 1 |
| Ilijevec, B; Jagric, T; Ocvirk, J; Potrc, S; Velenik, V | 1 |
| Allum, WH; Blazeby, JM; Cafferty, FH; Cunningham, D; Grabsch, HI; Griffin, SM; Langley, RE; Rowley, S; Smyth, EC | 1 |
| Hosone, M; Katayama, H; Makino, H; Seki, N; Takei, H; Ueda, J; Yokoyama, T; Yoshida, H | 1 |
| Bapat, B; Brown, J; Candrilli, SD; García-Foncillas, J; Kaye, JA; Liepa, AM; Lorenzen, S; Madhwani, S | 1 |
| Jain, A | 1 |
| Mini, E; Roviello, F; Roviello, G | 1 |
| Adenis, A; Mazard, T; Mourregot, A; Portales, F; Samalin, E; Ychou, M | 1 |
| Asleh, K; Brauer, HA; Chumsri, S; Joensuu, H; Lauttia, S; Lindman, H; Nielsen, TO; Sullivan, A; Thompson, EA | 1 |
| Cao, Y; Cui, S; Fan, Z; Fu, P; Guo, X; He, P; He, Q; Jiang, G; Jiang, J; Jin, F; Li, J; Li, X; Liu, P; Liu, Y; Ma, B; Mo, M; Pang, D; Qu, X; Rao, N; Ren, G; Shao, Z; Sheng, Y; Sun, Q; Tang, J; Wang, C; Wang, J; Wang, O; Wang, S; Wang, X; Xu, B; Yang, S; Yu, K; Yu, S; Zhang, G; Zhang, H; Zhang, J; Zhuang, Z | 1 |
| Bateman, A; Byrne, JP; Grace, BL; Iveson, T; Jackson, A; Kelly, JJ; Noble, F; Pucher, PH; Rahman, SA; Rees, C; Underwood, TJ; Walker, RC | 1 |
| Al-Batran, SE; Ganguli, A; Lordick, F; Morlock, R; Sahin, U; Türeci, Ö | 1 |
| Gęca, K; Małecka-Massalska, T; Mlak, R; Pelc, Z; Polkowski, WP; Rawicz-Pruszyński, K; Sędłak, K; Skórzewska, M | 1 |
| Ahlgren, J; Auvinen, P; Bono, P; Huovinen, R; Joensuu, H; Jukkola, A; Junnila, J; Kataja, V; Kellokumpu-Lehtinen, PL; Lahdenperä, O; Lindman, H; Nilsson, G; Nyandoto, P; Poikonen-Saksela, P; Tanner, M; Villman, K | 1 |
| Brugman, W; de Boo, LW; Hauptmann, M; Joensuu, H; Jóźwiak, K; Kluin, RJC; Kok, M; Lauttia, S; Lindman, H; Linn, SC; Nederlof, PM; Opdam, M; Schouten, PC; van Steenis, C | 1 |
| Allum, WH; Bhogal, RH; Chau, I; Chaudry, A; Cunningham, D; Fribbens, C; Gerlinger, M; Kumar, S; Malietzis, G; Moussa, O; Rao, S; Starling, N; Watkins, D | 1 |
| Amoroso, D; Barni, S; Bernardini, I; Bilancia, D; Casaretti, R; Cascinu, S; Casolaro, A; Cavanna, L; Cella, CA; Ciarlo, A; Codecà, C; Davite, C; Di Sanzo, A; Labianca, R; Luchena, G; Mosconi, S; Prisciandaro, M; Rosati, G; Silvestris, N; Zoratto, F | 1 |
| Deva, S; Findlay, M; Hitchen, N; Lawrence, B; Waldron, NR | 1 |
10 review(s) available for capecitabine and epirubicin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Design; Drug Synergism; Enzyme Induction; Epirubicin; Female; Fluorouracil; Humans; Irinotecan; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Thymidine Phosphorylase; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
[Gemcitabine-based combinations in inoperable pancreatic cancers].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Routes; Epirubicin; Fluorouracil; Gemcitabine; Humans; Irinotecan; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
Treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Economics, Pharmaceutical; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Anthracycline vs nonanthracycline adjuvant therapy for breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Methotrexate; Paclitaxel | 2004 |
Medical treatment for advanced gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2007 |
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Fatigue; Feasibility Studies; Female; Fluorouracil; Gastrointestinal Diseases; Germany; Hematologic Diseases; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2008 |
Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; In Situ Hybridization, Fluorescence; Meta-Analysis as Topic; Multicenter Studies as Topic; Neoplasm Metastasis; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2011 |
Breast carcinoma with choriocarcinomatous features: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Choriocarcinoma; Chorionic Gonadotropin; Cisplatin; Combined Modality Therapy; Cyclobutanes; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Giant Cells; Humans; Immunoenzyme Techniques; Kidney Neoplasms; Organoplatinum Compounds; Prognosis; Retrospective Studies; Taxoids | 2014 |
[Does the FLOT regimen a new standard of perioperative chemotherapy for localized gastric cancer?]
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease-Free Survival; Docetaxel; Epirubicin; Fluorouracil; Humans; Leucovorin; Oxaliplatin; Perioperative Care; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2020 |
90 trial(s) available for capecitabine and epirubicin
| Article | Year |
|---|---|
Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Palliative Care; Probability; Severity of Illness Index; Stomach Neoplasms; Survival Analysis; Treatment Outcome; United Kingdom | 2002 |
Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
[Metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Germany; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Patient Selection | 2003 |
An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Patient Compliance; Treatment Outcome | 2003 |
Application of a continual reassessment method to a phase I clinical trial of capecitabine in combination with cyclophosphamide and epirubicin (CEX) for inoperable or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local | 2004 |
Irinotecan, epirubicin, and capecitabine in metastatic adenocarcinomas: preliminary results of a phase I study.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Irinotecan; Male; Treatment Outcome | 2004 |
Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Filgrastim; Fluorouracil; Glucuronates; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pilot Projects; Polyethylene Glycols; Preoperative Care; Prospective Studies; Receptor, ErbB-2; Recombinant Proteins; Taxoids; Treatment Outcome | 2005 |
Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2005 |
Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cardiomyopathy, Dilated; Coronary Stenosis; Deoxycytidine; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Taxoids; Treatment Outcome | 2005 |
A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2005 |
Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Treatment Outcome | 2006 |
Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Premedication; Prospective Studies; Radionuclide Imaging; Remission Induction; Taxoids | 2006 |
A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Mastectomy, Radical; Middle Aged; Neoadjuvant Therapy; Survival Analysis; Treatment Outcome | 2007 |
Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Denmark; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Severity of Illness Index; Stomach Neoplasms; Survival Analysis; Time Factors; Treatment Outcome | 2007 |
Intra-arterial and systemic chemotherapy plus external hyperthermia in unresectable biliary cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Hyperthermia, Induced; Male; Middle Aged; Pilot Projects | 2007 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Quality of Life; Stomach Neoplasms; Survival Rate | 2008 |
Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Middle Aged | 2007 |
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Epirubicin; Female; Fluorouracil; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Topoisomerase II Inhibitors; Treatment Outcome | 2008 |
Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Treatment Outcome | 2009 |
Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Epirubicin; Esophagogastric Junction; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2008 |
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epirubicin; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Tissue Distribution; Treatment Outcome | 2008 |
Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Failure; Treatment Outcome | 2009 |
Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Anticoagulants; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Catheterization, Central Venous; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Stomach Neoplasms; Thromboembolism; United Kingdom; Warfarin | 2009 |
A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Stomach Neoplasms; Survival Rate | 2009 |
Gemcitabine-capecitabine plus intra-arterial epirubicin-cisplatin in pretreated pancreatic cancer patients: a phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Maximum Tolerated Dose; Pancreatic Neoplasms | 2009 |
Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fever; Fluorouracil; Humans; Lymph Nodes; Middle Aged; Mucositis; Neutropenia; Prospective Studies; Receptor, ErbB-2; Survival Analysis; Taxoids | 2010 |
A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma in Situ; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Period; Taxoids; Treatment Outcome | 2010 |
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Receptor, ErbB-2; Taxoids | 2009 |
Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neutropenia; Taxoids | 2010 |
A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome | 2010 |
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Germany; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Patient Compliance; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Trastuzumab; Treatment Outcome | 2010 |
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Germany; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Patient Compliance; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Trastuzumab; Treatment Outcome | 2010 |
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Fluorescent Antibody Technique; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplastic Cells, Circulating; Prospective Studies; Receptor, ErbB-2; Taxoids; Time Factors; Trastuzumab; Treatment Outcome | 2010 |
A phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) as first-line chemotherapy in advanced gastric cancer: a Chinese single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capecitabine; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Leukopenia; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2010 |
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate | 2010 |
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Stomach Neoplasms | 2010 |
Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dyspnea; Emotions; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Quality of Life; Regression Analysis; Sleep Initiation and Maintenance Disorders; Social Behavior; Surveys and Questionnaires; Sweden; Time Factors; Treatment Outcome; Young Adult | 2010 |
Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Prognosis; Risk Factors; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2010 |
The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pravastatin; Stomach Neoplasms | 2010 |
Clinical study of adjuvant capecitabine monotherapy in Chinese elderly patients (aged 55-70) with stage IIa breast cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; China; Cyclophosphamide; Cytarabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Treatment Outcome | 2010 |
Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Health Status; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Young Adult | 2012 |
Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life; Taxoids | 2011 |
Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Peritoneal Neoplasms; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate; Young Adult | 2012 |
Systemic gemcitabine and capecitabine plus intra-arterial epirubicin and cisplatin as second-line chemotherapy in gemcitabine-failure pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Failure | 2011 |
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Early Termination of Clinical Trials; Epirubicin; Female; Fluorouracil; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Quality of Life; Taxoids | 2011 |
Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Lymph Node Excision; Male; Neoadjuvant Therapy; Research Design; Stomach Neoplasms | 2011 |
Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Recurrence; Treatment Outcome | 2012 |
Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Finland; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2012 |
Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Incidence; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2012 |
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Myocardial Infarction; Stomach Neoplasms; Stroke Volume; Thromboembolism; Treatment Outcome | 2013 |
Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Treatment Outcome | 2013 |
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Early Termination of Clinical Trials; Epirubicin; ErbB Receptors; Esophageal Neoplasms; Female; Fluorouracil; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Proportional Hazards Models; Protein Kinase Inhibitors; Stomach Neoplasms; Time Factors; Treatment Outcome; United Kingdom | 2013 |
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Paclitaxel; Quality of Life; Treatment Outcome | 2013 |
Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Finland; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Proportional Hazards Models; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Diphosphonates; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Germany; Humans; Ibandronic Acid; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Young Adult | 2013 |
[Clinical paired study of comparing docetaxel plus capecitabine versus docetaxel plus epirubicin as first-line treatment in women with HER-2 negative advanced breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Taxoids | 2013 |
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuv
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Preoperative Care; Prognosis; Risk Factors; Taxoids; Treatment Outcome | 2013 |
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Neoadjuvant Therapy; Proportional Hazards Models; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
Adding preoperative radiotherapy plus cetuximab to perioperative chemotherapy for resectable esophageal adenocarcinoma: a single-center prospective phase II trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Chemoradiotherapy; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Perioperative Care; Preoperative Care; Prospective Studies; Survivors | 2014 |
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Taxoids; Treatment Outcome; Young Adult | 2014 |
[Prospective multicentric phase III study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Epirubicin; Fluorouracil; Germany; Humans; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prevalence; Risk Factors; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2014 |
A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triple Negative Breast Neoplasms; Young Adult | 2014 |
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Proportional Hazards Models; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2014 |
Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; France; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Prospective Studies; Quality of Life; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
Rilotumumab exposure-response relationship in patients with advanced or metastatic gastric cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Dose-Response Relationship, Drug; Epirubicin; Female; Hepatocyte Growth Factor; Humans; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Stomach Neoplasms | 2015 |
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2015 |
A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Routes; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Male; Methotrexate; Paclitaxel; Treatment Outcome | 2015 |
Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease-Free Survival; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Receptor, ErbB-2; Stomach Neoplasms | 2015 |
Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Odds Ratio; Taxoids; Treatment Outcome | 2015 |
(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Body Surface Area; Breast Neoplasms; Capecitabine; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Febrile Neutropenia; Female; Humans; Lymphatic Metastasis; Obesity; Taxoids | 2016 |
Assessment of pharmacokinetic interaction between rilotumumab and epirubicin, cisplatin and capecitabine (ECX) in a Phase 3 study in gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Cisplatin; Double-Blind Method; Drug Interactions; Epirubicin; Humans; Middle Aged; Models, Biological; Stomach Neoplasms; Young Adult | 2017 |
A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Epirubicin; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Frail Elderly; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Palliative Care | 2017 |
Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Finland; Fluorouracil; Humans; Middle Aged; Receptors, Estrogen; Receptors, Progesterone; Sweden; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2017 |
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Diphosphonates; Disease-Free Survival; Dose-Response Relationship, Drug; Early Diagnosis; Epirubicin; Female; Filgrastim; Germany; Humans; Ibandronic Acid; Middle Aged; Paclitaxel; Polyethylene Glycols; Young Adult | 2017 |
BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Capecitabine; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Myeloablative Agonists; Neoplasm Recurrence, Local; Paclitaxel; Triple Negative Breast Neoplasms | 2017 |
Immune gene expression and response to chemotherapy in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Breast Neoplasms; Capecitabine; Epirubicin; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2018 |
Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cisplatin; Combined Modality Therapy; Epirubicin; ErbB Receptors; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoadjuvant Therapy; Panitumumab; Perioperative Care; Prognosis; Societies, Medical; Stomach Neoplasms; Survival Rate | 2018 |
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate | 2019 |
The Effect of Supplementary Omegaven® on the Clinical Outcome of Patients With Advanced Esophagogastric Adenocarcinoma Receiving Palliative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy: A Phase II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Capecitabine; Cell Proliferation; Cytokines; Dietary Supplements; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Fatty Acids, Omega-3; Feasibility Studies; Female; Fish Oils; Humans; Male; Middle Aged; Oxaliplatin; Palliative Care; Pilot Projects; Prospective Studies; Stomach Neoplasms; Treatment Outcome; Triglycerides | 2019 |
Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro-oesophageal junction.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cisplatin; Clinical Protocols; Combined Modality Therapy; Epirubicin; Esophagogastric Junction; Gastrectomy; Humans; Quality Assurance, Health Care; Stomach; Stomach Neoplasms | 2019 |
Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Prognosis; Survival Rate; Triple Negative Breast Neoplasms | 2020 |
Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Prospective Studies; Time Factors; Triple Negative Breast Neoplasms | 2020 |
Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Claudins; Epirubicin; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Patient Reported Outcome Measures; Progression-Free Survival; Stomach Neoplasms; Surveys and Questionnaires; Treatment Outcome | 2021 |
Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans | 2022 |
Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Homologous Recombination; Humans; Triple Negative Breast Neoplasms | 2022 |
A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Docetaxel; Epirubicin; Fluorouracil; Humans; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2022 |
77 other study(ies) available for capecitabine and epirubicin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
[Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Leukopenia; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Neutropenia; Pilot Projects; Taxoids | 2006 |
Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms; Survival Analysis | 2006 |
[Patient with haemolytic anemia and treatment with capecitabine. Review of one case and literature].
Topics: Adult; Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gilbert Disease; Humans; Hyperbilirubinemia; Mastectomy, Segmental; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic | 2006 |
Metastatic esophageal adenocarcinoma presenting in the iris.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Iris Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2007 |
Evaluation of therapeutic efficacy of capecitabine on human breast carcinoma tissues and cell lines in vitro.
Topics: Adenosine Triphosphate; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Capecitabine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Epirubicin; Female; Flow Cytometry; Fluorouracil; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Ki-67 Antigen; Luminescence; Taxoids; Tetrazolium Salts | 2007 |
Oesophagectomy after definitive chemoradiation in patients with locally advanced oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Time Factors; Treatment Outcome | 2008 |
[A case of occult breast cancer successfully treated by capecitabine in combination with weekly paclitaxel followed by FEC (75)].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Paclitaxel; Positron-Emission Tomography; Treatment Outcome | 2008 |
Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neurotoxicity Syndromes | 2009 |
Blepharoptosis following oxaliplatin administration.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blepharoptosis; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Vision Disorders | 2009 |
Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Treatment Outcome; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2009 |
Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Soft Tissue Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2009 |
Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study.
Topics: Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Health Status Indicators; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2009 |
Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Platinum; Remission Induction; Retrospective Studies; Single-Blind Method; Stomach Neoplasms; Treatment Outcome | 2009 |
Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carboplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Modified Radical; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiodermatitis; Radiotherapy, Adjuvant; Retrospective Studies | 2010 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms | 2010 |
Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; gamma-Aminobutyric Acid; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Pregabalin | 2010 |
Outcomes from chemoradiotherapy for patients with esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Cardiotoxicity in patients treated with bevacizumab is potentially reversible.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Labeling; Early Termination of Clinical Trials; Epirubicin; Female; Fluorouracil; Heart Failure; Humans; Lymphoma, Large B-Cell, Diffuse; Meta-Analysis as Topic; Paclitaxel; Prednisone; Razoxane; Remission, Spontaneous; Rituximab; Trastuzumab; Vincristine | 2011 |
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
Topics: Adenocarcinoma; Antineoplastic Agents; Capecitabine; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Germany; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Salvage Therapy; Taxoids; Treatment Outcome | 2011 |
Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Epirubicin; Female; Fluorouracil; Gene Expression; Genes, erbB-2; Humans; Immunochemistry; In Situ Hybridization, Fluorescence; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Poly-ADP-Ribose Binding Proteins; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Risk of thromboembolic events after perioperative chemotherapy versus surgery alone for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Perioperative Care; Prognosis; Prospective Studies; Risk Factors; Thromboembolism | 2012 |
Nonsurgical management of esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Cohort Studies; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Survival Rate; Taxoids; Tomography, X-Ray Computed | 2012 |
Bilateral acute ptosis leading to the diagnosis of a presumed metastatic gastric adenocarcinoma.
Topics: Acute Disease; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blepharoptosis; Capecitabine; Deoxycytidine; Epirubicin; Fatal Outcome; Fluorouracil; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Orbital Neoplasms; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Stomach Neoplasms; Tomography, X-Ray Computed | 2012 |
A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Carboplatin; Confidence Intervals; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Fluorouracil; Gemcitabine; Health Services Accessibility; Humans; Logistic Models; Lymphatic Metastasis; Medication Adherence; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Odds Ratio; Paclitaxel; Receptors, Estrogen; Switzerland; Taxoids; Vinblastine; Vinorelbine | 2012 |
Effects of neo-adjuvant chemotherapy for oesophago-gastric cancer on neuro-muscular gastric function.
Topics: Acetylcholinesterase; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carbachol; Chemotherapy, Adjuvant; Cholinergic Agonists; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Ganglia, Autonomic; Gastric Emptying; Gastric Mucosa; Humans; In Vitro Techniques; Male; Middle Aged; Muscle Contraction; Muscle, Smooth; Neoadjuvant Therapy; Stomach; Stomach Neoplasms | 2012 |
Differential pathological response to preoperative chemotherapy across breast cancer intrinsic subtypes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; ErbB Receptors; Female; Fluorouracil; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Odds Ratio; Receptor, ErbB-2; Taxoids | 2012 |
Postoperative chemoradiotherapy combined with epirubicin-based triplet chemotherapy for locally advanced adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Postoperative Period; Retrospective Studies; Stomach | 2013 |
Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Stomach Neoplasms | 2013 |
Breast cancer drugs dampen vascular functions by interfering with nitric oxide signaling in endothelium.
Topics: Animals; Antineoplastic Agents; Capecitabine; Cattle; Cells, Cultured; Deoxycytidine; Dose-Response Relationship, Drug; Endothelial Cells; Epirubicin; Fluorouracil; Gene Expression Regulation, Enzymologic; Humans; Models, Molecular; Molecular Structure; Nitric Oxide; Nitric Oxide Synthase Type III; Protein Conformation; Protein Structure, Tertiary; Signal Transduction; Tamoxifen | 2013 |
Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Catheterization, Peripheral; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Humans; Length of Stay; Male; Middle Aged; Neoadjuvant Therapy; Perioperative Period; Pulmonary Embolism; Retrospective Studies; Stomach Neoplasms; Survival Rate; Venous Thromboembolism; Venous Thrombosis; Young Adult | 2014 |
Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Retrospective Studies; Taxoids; Treatment Outcome; Upper Gastrointestinal Tract | 2013 |
The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Gastrectomy; Hospitals, University; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Prospective Studies; Stomach Neoplasms; United Kingdom | 2014 |
Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Trastuzumab | 2014 |
Different methods of pretreatment Ki-67 labeling index evaluation in core biopsies of breast cancer patients treated with neoadjuvant chemotherapy and their relation to response to therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Cell Proliferation; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Neoadjuvant Therapy; Retrospective Studies; Taxoids | 2015 |
Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2015 |
Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Sarcopenia; Stomach Neoplasms; Tomography, X-Ray Computed | 2015 |
Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Perioperative Care; Prognosis; Retrospective Studies; Safety; Stomach Neoplasms; Survival Rate; Time Factors | 2015 |
Treatment-related frequency of venous thrombosis in lower esophageal, gastro-esophageal and gastric cancer--a clinical prospective study of outcome and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Epirubicin; Esophageal Neoplasms; Female; Humans; Incidence; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Prospective Studies; Pulmonary Embolism; Recurrence; Risk Factors; Stomach Neoplasms; Treatment Outcome; Venous Thrombosis | 2015 |
High Impact of Histopathological Remission for Prognosis after Perioperative Chemotherapy with ECF and ECF-Like Regimens for Gastric and Gastroesophageal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Perioperative Period; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2015 |
Perioperative chemotherapy in gastroesophageal cancer. A retrospective monocenter evaluation of 42 cases.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Diarrhea; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Leukopenia; Male; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Perioperative Care; Retrospective Studies; Stomach; Stomach Neoplasms; Survival Analysis | 2015 |
Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Administration Schedule; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2015 |
The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Capecitabine; Cell Nucleus; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Phosphoproteins; Reference Values; Retrospective Studies; Sodium-Hydrogen Exchangers; Stomach Neoplasms; Treatment Outcome | 2015 |
Prognostic impact of preoperative platelets to lymphocytes ratio (PLR) on survival for oesophageal and junctional carcinoma treated with neoadjuvant chemotherapy: A retrospective monocentric study on 153 patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Studies; Disease-Free Survival; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Humans; Lymphocyte Count; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Platelet Count; Preoperative Period; Prognosis; Retrospective Studies; ROC Curve; Survival Rate | 2015 |
Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Gastrectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Postoperative Period; Prospective Studies; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2015 |
Corneal Confocal Microscopy Detects Small Fibre Neuropathy in Patients with Upper Gastrointestinal Cancer and Nerve Regeneration in Chemotherapy Induced Peripheral Neuropathy.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cold Temperature; Cornea; Epirubicin; Erythromelalgia; Esophageal Neoplasms; Female; Hot Temperature; Humans; Hyperalgesia; Liver Neoplasms; Male; Microscopy, Confocal; Middle Aged; Nerve Fibers; Nerve Regeneration; Neural Conduction; Organoplatinum Compounds; Oxaliplatin; Pain Threshold; Stomach Neoplasms; Trastuzumab; Vibration | 2015 |
Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Cell Cycle Proteins; Class I Phosphatidylinositol 3-Kinases; Cyclophosphamide; DNA Mutational Analysis; Docetaxel; Epirubicin; Gene Expression; Humans; Middle Aged; Mutation; Phosphoproteins; PTEN Phosphohydrolase; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2016 |
Full robot-assisted gastrectomy: surgical technique and preliminary experience from a single center.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Surgical; Blood Transfusion; Capecitabine; Combined Modality Therapy; Drug Administration Schedule; Epirubicin; Female; Gastrectomy; Humans; Infusions, Intravenous; Learning Curve; Male; Middle Aged; Operative Time; Organoplatinum Compounds; Oxaliplatin; Perioperative Care; Prospective Studies; Robotic Surgical Procedures; Stomach Neoplasms; Young Adult | 2016 |
Antibody Improves Survival in Gastric Cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Disease-Free Survival; Epirubicin; Humans; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2016 |
Plasma and erythrocyte uptake of omega-3 fatty acids from an intravenous fish oil based lipid emulsion in patients with advanced oesophagogastric cancer.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Epirubicin; Erythrocyte Membrane; Erythrocytes; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Fatty Acids, Omega-3; Feasibility Studies; Female; Fish Oils; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Phosphatidylcholines; Pilot Projects; Prospective Studies; Reproducibility of Results; Sample Size; Stomach Neoplasms; Treatment Outcome; United Kingdom | 2017 |
Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxaloacetates; Preoperative Care; Prospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Stomach Neoplasms; United Kingdom | 2017 |
Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Disease Progression; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Netherlands; Paclitaxel; Propensity Score; Thromboembolism | 2017 |
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Perioperative Care; Preoperative Care; Prognosis; Prospective Studies; Retrospective Studies; Stomach Neoplasms; Survival Rate | 2017 |
[Multimodal therapy for gastric or gastroesophageal junction adenocarcinoma -ECF vs. FLOT].
Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therapy; Oxaliplatin | 2017 |
Lymphoepithelioma-Like Carcinoma of the Esophagus: A Rare Tumor.
Topics: Antineoplastic Agents; Biopsy; Capecitabine; Carcinoma; Cisplatin; Epirubicin; Esophageal Neoplasms; Esophagectomy; Female; Humans; Immunohistochemistry; Middle Aged; Treatment Outcome | 2017 |
Taxane Followed by Anthracycline or Vice Versa: Impact of Sequential Order on Breast Cancer Recurrence?-Reply.
Topics: Anthracyclines; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cyclophosphamide; Docetaxel; Epirubicin; Humans; Neoplasm Recurrence, Local; Taxoids | 2018 |
Taxane Followed by Anthracycline or Vice Versa: Impact of Sequential Order on Breast Cancer Recurrence?
Topics: Anthracyclines; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cyclophosphamide; Docetaxel; Epirubicin; Humans; Neoplasm Recurrence, Local; Taxoids | 2018 |
Surgical morbidity and mortality after neoadjuvant chemotherapy in the CRITICS gastric cancer trial.
Topics: Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Epirubicin; Esophagectomy; Female; Gastrectomy; Humans; Induction Chemotherapy; Logistic Models; Lymph Node Excision; Male; Middle Aged; Mortality; Multivariate Analysis; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Randomized Controlled Trials as Topic; Risk Factors; Sex Factors; Splenectomy; Stomach Neoplasms | 2018 |
Perioperative ECX chemotherapy in older adults with gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Treatment Outcome | 2018 |
Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carboplatin; Cell Proliferation; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Drug Screening Assays, Antitumor; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Trastuzumab; Young Adult | 2018 |
The Role of Continuing Perioperative Chemotherapy Post Surgery in Patients with Esophageal or Gastroesophageal Junction Adenocarcinoma: a Multicenter Cohort Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Humans; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Perioperative Period; Propensity Score; Retrospective Studies; Survival Rate | 2019 |
Perioperative EOX treatment in operable locally advanced gastroesophageal adenocarcinoma: Prediction of tumor response by FDG -PET and histopathology.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Oxaliplatin; Perioperative Care; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Stomach Neoplasms; Survival Rate; Young Adult | 2019 |
Perioperative FLOT: new standard for gastric cancer?
Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Humans; Leucovorin; Oxaliplatin; Stomach Neoplasms | 2019 |
Perioperative FLOT superior to ECF/X.
Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Humans; Leucovorin; Oxaliplatin | 2019 |
Impact of perioperative treatment on survival of resectable gastric cancer patients after D2 lymphadenectomy: a single European centre propensity score matching analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Epirubicin; Female; Fluorouracil; Humans; Lymph Node Excision; Male; Middle Aged; Oxaliplatin; Perioperative Care; Propensity Score; Stomach Neoplasms | 2019 |
Capecitabine + Epirubicin + Cyclophosphamide Combination Therapy (CEX Therapy) as Neoadjuvant Chemotherapy for HER-2-Negative Breast Cancer: A Retrospective, Single-Center Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Precision Medicine; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome | 2020 |
Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Analgesics, Opioid; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease Progression; Docetaxel; Emergency Service, Hospital; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; France; Germany; Guideline Adherence; Hospice Care; Hospitalization; Humans; Irinotecan; Male; Middle Aged; Nutritional Support; Oxaliplatin; Palliative Care; Practice Guidelines as Topic; Practice Patterns, Physicians'; Receptor, ErbB-2; Retrospective Studies; Spain; Stomach Neoplasms; Treatment Failure; United Kingdom | 2020 |
Perioperative chemotherapy for gastric cancer in FLOT4.
Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Humans; Leucovorin; Oxaliplatin; Stomach Neoplasms | 2020 |
Perioperative chemotherapy for gastric cancer in FLOT4.
Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Humans; Leucovorin; Oxaliplatin; Stomach Neoplasms | 2020 |
Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Disease-Free Survival; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Hospital Mortality; Humans; Length of Stay; Leucovorin; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Postoperative Complications; Propensity Score; Survival Rate; Treatment Outcome | 2020 |
Union is strength: Textbook outcome with perioperative chemotherapy compliance decreases the risk of death in advanced gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Docetaxel; Epirubicin; Female; Fluorouracil; Gastrectomy; Guideline Adherence; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Outcome and Process Assessment, Health Care; Oxaliplatin; Perioperative Care; Postoperative Complications; Practice Guidelines as Topic; Stomach Neoplasms; Survival Rate | 2022 |
Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Studies; Docetaxel; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Leucovorin; Oxaliplatin; Perioperative Care; Propensity Score; Stomach Neoplasms; Treatment Outcome | 2022 |
Real-world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Febrile Neutropenia; Gemcitabine; Humans; Middle Aged; Palliative Care; Pancreatic Neoplasms; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2023 |